Posts Tagged ‘anti-competitive practices’

Dreaming of a Bigger Ban on Competition for Obesity Drugs

October 27, 2024 — It seems that both Novo Nordisk and Eli Lilly are dreaming of a bigger ban on competition for their wildly successful obesity drugs. With semaglutide and tirzepatide, they have valuable assets that meet a tremendous medical need. And they really do not like the compounding pharmacies taking big bites from their apples. So this week, […]

Generic Liraglutide Is Here – Will It Make Any Difference?

June 26, 2024 — One of the four dimensions that sum to a terrible problem of inadequate scale in obesity care is cost. Right now, the list prices for obesity medicines like semaglutide and tirzepatide in the U.S. put them out of reach for all but the wealthy and the well-insured. So will it help that a generic GLP-1 agonist – […]

Patent Thickets to Boost Obesity Medicine Prices

February 9, 2024 — Are patent thickets boosting the prices of obesity medicine prices and putting these important medical advances out of reach for everyone but the wealthy and well insured? A new paper in JAMA this week suggests this is true – at least in part. Rasha Alhiary and colleagues explain: “Manufacturers have secured long periods of market […]